Based on the observation that the overall incidence of HER2/neu gene amplification/protein overexpression in invasive carcinoma is lower in invasive carcinoma than in DCIS, other investigators suggested that other molecular events might be more critical in the progression from in situ to invasive cancer(36). The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.